These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

264 related items for PubMed ID: 19737884

  • 1. Trichostatin A-induced TGF-beta type II receptor expression in retinoblastoma cell lines.
    Kashiwagi Y, Horie K, Kanno C, Inomata M, Imamura T, Kato M, Yamamoto T, Yamashita H.
    Invest Ophthalmol Vis Sci; 2010 Feb; 51(2):679-85. PubMed ID: 19737884
    [Abstract] [Full Text] [Related]

  • 2. Lack of transforming growth factor-beta type II receptor expression in human retinoblastoma cells.
    Horie K, Yamashita H, Mogi A, Takenoshita S, Miyazono K.
    J Cell Physiol; 1998 Jun; 175(3):305-13. PubMed ID: 9572475
    [Abstract] [Full Text] [Related]

  • 3. Heterogeneous transforming growth factor (TGF)-beta unresponsiveness and loss of TGF-beta receptor type II expression caused by histone deacetylation in lung cancer cell lines.
    Osada H, Tatematsu Y, Masuda A, Saito T, Sugiyama M, Yanagisawa K, Takahashi T.
    Cancer Res; 2001 Nov 15; 61(22):8331-9. PubMed ID: 11719467
    [Abstract] [Full Text] [Related]

  • 4. Requirement of a specific Sp1 site for histone deacetylase-mediated repression of transforming growth factor beta Type II receptor expression in human pancreatic cancer cells.
    Zhao S, Venkatasubbarao K, Li S, Freeman JW.
    Cancer Res; 2003 May 15; 63(10):2624-30. PubMed ID: 12750289
    [Abstract] [Full Text] [Related]

  • 5. MS-275, a histone deacetylase inhibitor, selectively induces transforming growth factor beta type II receptor expression in human breast cancer cells.
    Lee BI, Park SH, Kim JW, Sausville EA, Kim HT, Nakanishi O, Trepel JB, Kim SJ.
    Cancer Res; 2001 Feb 01; 61(3):931-4. PubMed ID: 11221885
    [Abstract] [Full Text] [Related]

  • 6. Histone modification in the TGFbetaRII gene promoter and its significance for responsiveness to HDAC inhibitor in lung cancer cell lines.
    Osada H, Tatematsu Y, Sugito N, Horio Y, Takahashi T.
    Mol Carcinog; 2005 Dec 01; 44(4):233-41. PubMed ID: 16163707
    [Abstract] [Full Text] [Related]

  • 7. Trichostatin A and structurally related histone deacetylase inhibitors induce 5-lipoxygenase promoter activity.
    Klan N, Seuter S, Schnur N, Jung M, Steinhilber D.
    Biol Chem; 2003 May 01; 384(5):777-85. PubMed ID: 12817474
    [Abstract] [Full Text] [Related]

  • 8. Decreased expression of TGF-beta cell surface receptors during progression of human oral squamous cell carcinoma.
    Paterson IC, Matthews JB, Huntley S, Robinson CM, Fahey M, Parkinson EK, Prime SS.
    J Pathol; 2001 Apr 01; 193(4):458-67. PubMed ID: 11276004
    [Abstract] [Full Text] [Related]

  • 9. miR-106b aberrantly expressed in a double transgenic mouse model for Alzheimer's disease targets TGF-β type II receptor.
    Wang H, Liu J, Zong Y, Xu Y, Deng W, Zhu H, Liu Y, Ma C, Huang L, Zhang L, Qin C.
    Brain Res; 2010 Oct 21; 1357():166-74. PubMed ID: 20709030
    [Abstract] [Full Text] [Related]

  • 10. Overexpression of transforming growth factor (TGF) beta1 type II receptor restores TGF-beta1 sensitivity and signaling in human prostate cancer cells.
    Guo Y, Kyprianou N.
    Cell Growth Differ; 1998 Feb 21; 9(2):185-93. PubMed ID: 9486855
    [Abstract] [Full Text] [Related]

  • 11. Characterization of TGF-beta-regulated interleukin-8 expression in human prostate cancer cells.
    Lu S, Dong Z.
    Prostate; 2006 Jun 15; 66(9):996-1004. PubMed ID: 16541418
    [Abstract] [Full Text] [Related]

  • 12. Deletion of one adenine base within the polyadenine tract of transforming growth factor-beta receptor type II in human MDA-MB-231 breast cancer cell line.
    Park B, Jang JS, Park K.
    Int J Oncol; 2000 Sep 15; 17(3):473-8. PubMed ID: 10938386
    [Abstract] [Full Text] [Related]

  • 13. Glioma gene therapy with soluble transforming growth factor-beta receptors II and III.
    Naumann U, Maass P, Gleske AK, Aulwurm S, Weller M, Eisele G.
    Int J Oncol; 2008 Oct 15; 33(4):759-65. PubMed ID: 18813789
    [Abstract] [Full Text] [Related]

  • 14. Loss of functional transforming growth factor (TGF)-beta type II receptor results in insensitivity to TGF-beta1-mediated apoptosis and Epstein-Barr virus reactivation.
    Fukuda M, Kurosaki H, Sairenji T.
    J Med Virol; 2006 Nov 15; 78(11):1456-64. PubMed ID: 16998876
    [Abstract] [Full Text] [Related]

  • 15. Sequence-specific enhancer binding protein is responsible for the differential expression of ERT/ESX/ELF-3/ESE-1/jen gene in human gastric cancer cell lines: Implication for the loss of TGF-beta type II receptor expression.
    Park SH, Kim YS, Park BK, Hougaard S, Kim SJ.
    Oncogene; 2001 Mar 08; 20(10):1235-45. PubMed ID: 11313868
    [Abstract] [Full Text] [Related]

  • 16. Farnesyltransferase inhibitor (L-744,832) restores TGF-beta type II receptor expression and enhances radiation sensitivity in K-ras mutant pancreatic cancer cell line MIA PaCa-2.
    Alcock RA, Dey S, Chendil D, Inayat MS, Mohiuddin M, Hartman G, Chatfield LK, Gallicchio VS, Ahmed MM.
    Oncogene; 2002 Nov 07; 21(51):7883-90. PubMed ID: 12420225
    [Abstract] [Full Text] [Related]

  • 17. Molecular sequelae of histone deacetylase inhibition in human retinoblastoma cell lines: clinical implications.
    Poulaki V, Mitsiades CS, Kotoula V, Negri J, McMullan C, Miller JW, Marks PA, Mitsiades N.
    Invest Ophthalmol Vis Sci; 2009 Sep 07; 50(9):4072-9. PubMed ID: 19387079
    [Abstract] [Full Text] [Related]

  • 18. Stimulation of the murine type II transforming growth factor-beta receptor promoter by the transcription factor Egr-1.
    Wilder PJ, Bernadt CT, Kim JH, Rizzino A.
    Mol Reprod Dev; 2002 Nov 07; 63(3):282-90. PubMed ID: 12237943
    [Abstract] [Full Text] [Related]

  • 19. Mechanism of induction of transforming growth factor-beta type II receptor gene expression by v-Src in murine myeloid cells.
    Park SH, Birchenall-Roberts MC, Yi Y, Lee BI, Lee DK, Bertolette DC, Fu T, Ruscetti F, Kim SJ.
    Cell Growth Differ; 2001 Jan 07; 12(1):9-18. PubMed ID: 11205746
    [Abstract] [Full Text] [Related]

  • 20. Defective transforming growth factor beta signaling pathway in head and neck squamous cell carcinoma as evidenced by the lack of expression of activated Smad2.
    Muro-Cacho CA, Rosario-Ortiz K, Livingston S, Muñoz-Antonia T.
    Clin Cancer Res; 2001 Jun 07; 7(6):1618-26. PubMed ID: 11410498
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.